. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: J Clin Immunol. 2019 Jul 16;39(6):532–556. doi: 10.1007/s10875-019-00665-w

Table 3.

Outcomes after immune modulation therapy in WHIM patients. Ig, supplemental immunoglobulin (IV or subcutaneous route of administration); HSC, hematopoietic stem cell. Adverse events are those attributed to the treatment.

		Clinical Response (n)
Treatment	n	Improved	Not Improved	Not Mentioned	Adverse events (n)
G-CSF	59	24	9	28	thrombocytopenia (3) myelofibrosis (1) bone pain
GM-CSF	4	3	-	1	myelofibrosis (1) bone pain
Ig	33	6	1	21	allergic reaction (1)
Plerixafor	11	11 (Hematologic) 5 (Clinical)	0	-	None observed
HSC Transplantation	4	4 (Cured)	0	-	bronchitis flare (1) mild skin GVHD (1)